Overview

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

Status:
Completed

Trial end date:
2011-10-26

Target enrollment:

Participant gender:

Summary

The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Lisdexamfetamine Dimesylate